Citius Oncology's LYMPHIR sales double in Q4 2026 with growing institutional demand for CTCL treatment.

Citius Oncology reported that LYMPHIR unit sales to U.S. wholesalers more than doubled in the fiscal fourth quarter ended September 30, 2026, reaching 792 units compared to 360 units in the previous quarter. The company is expanding its commercial reach nationwide and aims to have LYMPHIR on formulary at 100 priority institutions by the end of 2026. LYMPHIR, approved by the FDA in December 2025, is a targeted immunotherapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL). Citius Oncology expects continued sales growth and deeper market penetration in 2027 as LYMPHIR becomes more established in treating CTCL.

As of Oct 27, 2026 00:11 WIB, shares of Citius Pharmaceuticals Inc (CTXR) are trading at USD 0.45 on Pluang, showing a strong 1-day gain of 11.55%. The stock's market capitalization stands at $10.85 million with a trading volume of 433,052. This notable price increase coincides with the company's reported 120% growth in LYMPHIR unit shipments during the fiscal fourth quarter of 2026.